ImageneBio (NASDAQ:IMA) Issues Earnings Results, Beats Estimates By $0.27 EPS

ImageneBio (NASDAQ:IMA) issued its quarterly earnings data on Wednesday. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.27, FiscalAI reports.

ImageneBio Stock Performance

ImageneBio stock traded down $0.03 during mid-day trading on Friday, reaching $5.60. The stock had a trading volume of 19,355 shares, compared to its average volume of 160,248. The firm has a market capitalization of $59.63 million, a PE ratio of -0.96 and a beta of 0.76. The stock’s 50-day simple moving average is $5.77 and its 200-day simple moving average is $5.96. ImageneBio has a fifty-two week low of $3.94 and a fifty-two week high of $15.79.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on IMA shares. Wall Street Zen downgraded shares of ImageneBio from a “sell” rating to a “strong sell” rating in a research note on Sunday, May 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImageneBio in a research report on Monday, June 29th. Finally, Wedbush reaffirmed an “underperform” rating on shares of ImageneBio in a report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $30.00.

Institutional Trading of ImageneBio

Several institutional investors and hedge funds have recently modified their holdings of the stock. Deep Track Capital LP purchased a new position in shares of ImageneBio during the third quarter valued at approximately $7,160,000. Blue Owl Capital Holdings LP lifted its stake in ImageneBio by 52.3% during the 4th quarter. Blue Owl Capital Holdings LP now owns 823,785 shares of the company’s stock valued at $5,684,000 after acquiring an additional 282,861 shares in the last quarter. Vanguard Group Inc. bought a new position in ImageneBio during the 3rd quarter valued at $1,902,000. BML Capital Management LLC boosted its holdings in ImageneBio by 13.4% during the 1st quarter. BML Capital Management LLC now owns 200,730 shares of the company’s stock worth $1,004,000 after acquiring an additional 23,704 shares during the last quarter. Finally, BlackRock Inc. purchased a new position in ImageneBio during the 2nd quarter worth $797,000. 75.00% of the stock is owned by hedge funds and other institutional investors.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.